Search

Displaying results 1331 - 1340 of 8468 in total
  1. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc. … [A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely

  2. Drug

    Fluoxymesterone

    go.drugbank.com/drugs/DB01185
    ApprovedIllicit

    An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.

  3. Drug

    Phenoxymethylpenicillin

    go.drugbank.com/drugs/DB00417
    ApprovedInvestigationalVet approved

    Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. … Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK.[A178609] It is a phenoxymethyl analog of Penicillin G, or [benzylpenicillin].

  4. Drug

    Panthenol

    go.drugbank.com/drugs/DB11204
    Approved

    Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties [A32377]. … Panthenol exists as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol).

  5. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride. … It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.

  6. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    [A255647,L44612] In March 2025, an extended-release formulation of diazoxide choline was approved by the FDA for the treatment of hyperphagia in patients with Prader-Willi syndrome, becoming the first

  7. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018

  8. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]

  9. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122]. … It has affinity for T-cells, accessory immune cells, and cancer cells.

  10. Drug

    Triethylenetetramine

    go.drugbank.com/drugs/DB06824
    ApprovedInvestigational

    TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. … [L41730] TETA has been investigated in clinical trials for the treatment of heart failure in patients with diabetes.[A18804,A19332,A19333,A19334,A19335]